Adagene Inc (ADAG) Price

Adagene Gains 14% as FDA Fast-Tracks Cancer Therapy

Adagene Inc. shares rose 13.77% after the FDA granted Fast Track designation for its colorectal cancer drug, muzastotug, on December 16, 2025.

eXoZymes Reports Major Biomanufacturing Scale-Up

eXoZymes Inc. announced a successful 100-fold scale-up of its proprietary biomanufacturing process for the molecule NCT, achieving over 99% conversion efficiency. The news triggered a significant positive market reaction, with the company's stock gaining over 14% on elevated trading volume.

Adagene Secures Licensing Deal with Third Arc Bio for Cancer Therapy Platform, Valued Up to $840M